Bookmark and Share
BioAssay: AID 504878

Inhibitors of USP1/UAF1: Summary

Deubiquitinating enzymes (DUBs) are a class of enzymes that can cleave isopeptide bond formed between the C-terminal carboxylate of ubiquitin and a lysine side-chain amino group on the target protein. Among them, ubiquitin specific proteases (USPs) constitute the largest DUB family. Human USPs are emerging as promising targets for pharmacological intervention because of their connection to a more ..
_
   
AID: 504878
Data Source: NCGC (USP1000)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-06-29
Target
Depositor Specified Assays
Show more
AIDNameTypeComment
504865Inhibitors of USP1/UAF1: Pilot qHTSconfirmatory
651626Inhibitors of USP1/UAF1: SAR in USP2 diubiquitin SDS-PAGE gel assayother
624345Inhibitors of USP1/UAF1: Hit Validation in USP2 Diubiquiting Gel Assayother
651621Inhibitors of USP1/UAF1: SAR in USP1/UAF1 diubiquitin SDS-PAGE gel assayother
651622Inhibitors of USP1/UAF1: SAR in USP46/UAF1 diubiquitin SDS-PAGE gel assayother
651623Inhibitors of USP1/UAF1: SAR in USP8 diubiquitin SDS-PAGE gel assayother
624346Inhibitors of USP1/UAF1: Hit Validation in USP1 Diubiquiting Gel Assayother
651624Inhibitors of USP1/UAF1: SAR in USP7 diubiquitin SDS-PAGE gel assayother
540327Inhibitors of USP1/UAF1: Hit Validation in Primary Assayconfirmatory
651605Inhibitors of USP1/UAF1: SAR in Primary Assayconfirmatory
651625Inhibitors of USP1/UAF1: SAR in USP5 diubiquitin SDS-PAGE gel assayother
743255Inhibitors of USP1/UAF1: Primary Screenconfirmatory
624341Inhibitors of USP1/UAF1: Hit Validation in USP7 Diubiquiting Gel Assayother
Description:
Deubiquitinating enzymes (DUBs) are a class of enzymes that can cleave isopeptide bond formed between the C-terminal carboxylate of ubiquitin and a lysine side-chain amino group on the target protein. Among them, ubiquitin specific proteases (USPs) constitute the largest DUB family. Human USPs are emerging as promising targets for pharmacological intervention because of their connection to a number of human diseases, including prostate, colon and breast cancer (1, 2), pediatric acute lymphoblastic leukemia (3), and familial cylindromatosis (4). The advantage of inhibiting USPs lies in the potential specificity of therapeutic intervention that can lead to better efficacy and reduce nonspecific side effects.

In a collaboration between the University of Delaware and the NIH Chemical Genomics Center, a high-throughput screen assay was developed to screen for USP1/UAF1 inhibitors. This miniaturized assay has a fluorescent read-out and is used to screen the NIH Molecular Libraries Small Molecule Repository (MLSMR) in order to identify a small molecule that inhibits USP1. Follow-up assays have also been developed to further test the hits from the primary screen.

NIH Chemical Genomics Center [NCGC]
NIH Molecular Libraries Probe Centers Network [MLPCN]

MLPCN Grant: DA030552-01
Assay Submitter (PI): Zhihao Zhuang, University of Delaware

1. Priolo, C., et al. (2006) The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 66, 8625-8632

2. Popov, N., et al. (2007) The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9, 765-774

3. De Pitta, C., et al. (2005) A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica 90, 890-898

4. Kovalenko, A., et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805
Protocol
Please see linked AIDs for a detailed protocol for a specific assay.
Comment
This project is on-going and will be updated at a later point with findings.
Additional Information
Grant Number: DA030552

PageFrom: